• Mechanism of Action
• Inhibits epidermal growth factor receptor (EGFR), a transmembrane amino acid receptor tyrosine kinase found in approximately 15% of non small cell lung cancers.
  EGFR mutations affect downstream signalling pathways resulting in cell proliferation
  Inhibition of these receptors disrupts this proliferation pathway.

Clinical Use

• • Indications
  • Advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutation
  • Locally advanced or metastatic non-small cell lung cancer after failure of primary chemotherapy
  • Locally advanced, unresectable or metastatic pancreatic cancer
• • Adverse Effects
  • Acneiform rash
  • Diarrhoea
  • Ocular changes
  • Alopecia
  • Nail changes
  • Interstitial lung disease